Recent publications [1, 2] about the considerable decline of the female breast cancer
incidence of estrogen receptor positive cancers among women aged 50–69 years in the …

Introduction. ER, PR, and HER2 are routinely available in breast cancer specimens. The
purpose of this study is to contrast breast cancer‐specific survival for the eight ER/PR/HER2 …

Purpose To examine gender-specific differences in breast cancer utilizing the National
Cancer Data Base (NCDB). Methods Breast cancer patients entered in the NCDB from 1998 …

Breast Cancer, Second Editionis intended to provide a comprehensive description of current
and evolving aspects of breast cancer including the biologic basis of disease, epidemiology …

Male breast cancer accounts for approximately 1% of all breast cancer. To date, risk factors
for male breast cancer are poorly defined, but certain risk factors and genetic features …

Introduction Estrogen receptor (ER) and progesterone receptor (PR) testing are performed in
the evaluation of breast cancer. While the clinical utility of ER as a predictive biomarker to …

Background Male breast cancer (MBC) is a rare disease for which there is limited
understanding of treatment patterns and prognostic factors. Methods Men with TNM stage I …

To characterize male breast cancer in Africa in recent decades, we systematically reviewed
literature and conducted a meta-analysis of available data on male breast cancer in Africa. A …

As far as recent breast cancer molecular subtype classification is concerned, much work has
dealt with clinical outcomes for triple negative and Her2 patients. Less is known about the …

Little information is available on the survival of male breast cancer patients because the
disease is extremely rare in men. Moreover, previous reports on the prognosis of male …